Explore the Agenda
7:15 am Morning Registration & Light Breakfast
8:20 am Chair’s Opening Remarks
Harnessing Liquid Biopsy to Escalate, De-Escalate & Switch Treatment for Improved Survival & Reduced Patient Burden
8:30 am Building on SERENA-6: Advancing the Next Generation of ctDNA-Guided Clinical Programs
- Exploring where ctDNA is already informing clinical decision making today, using SERENA-6 as a leading example of acting on molecular resistance before imaging progression
- Building from established resistance monitoring toward longitudinal ctDNA strategies that can identify molecular progression ahead of imaging and enable earlier clinical decisions
- Looking ahead to emerging approaches such as functional liquid biopsy and integration with imaging to shape the future of ctDNA-guided care
9:00 am Session Reserved for Guardant Health
- Presentation details to be announced
9:30 am Panel Discussion: Acting on Molecular Progression to Improve Therapeutic Decision Making Before Imaging Detects Resistance
- Determining how much molecular change justifies a switch when the scan still reads stable
- Weighing the risk of switching too early against the cost of waiting for radiographic confirmation
- Establishing what evidence oncologists and payers need before molecular progression becomes an accepted trigger
10:00 am Session Reserved for Foundation Medicine
- Presentation details to be announced
10:30 am Morning Break & Refreshments
11:00 am One-to-One Meetings & Structured Networking
A dedicated window for strategic one-to-one discussions and targeted networking, enabling attendees to strengthen key relationships and have purposeful conversations that drive meaningful outcomes in precision medicine.
Building on MRD-Defined Patient Selection to Take Residual Disease from Retrospective Analysis into Prospective Trial Design
11:30 am Moving MRD from a Prognostic Signal to a Decision-Making Diagnostic: Lessons from Bladder Cancer
- Breaking down the MRD label into distinct intended uses, and why each demands a different level of proof
- Defining the clinical decision points where MRD results change what happens to the patient
- Applying that framework to bladder cancer, including early learnings from a urinebased MRD application
- Assessing what regulators will need to see before MRD-guided decisions become standard of care, and what the first companion diagnostic signals for the field
12:00 pm Session Reserved for Myriad Genetics
- Presentation details to be announced
12:30 pm Longitudinal Molecular Response Monitoring with ctDNA in ADC-Treated Solid Tumors
- Presenting new data to track ctDNA molecular response against clinical outcome to assess how early blood-based dynamics reflect treatment benefit in patients receiving ADCs
- Examining how longitudinal monitoring performs across a pan-tumor population, highlighting where molecular response adds value beyond standard imaging
- Discusses practical implications for using molecular response to inform clinical development strategy and therapeutic decision making in ADC programs
1:00 pm Session Reserved for Natera
- Presentation details to be announced
1:30 pm Lunch Break & Networking
Track A: Dose Optimization & Therapeutic Monitoring
Chair: Julia Di Lulio, Senior Director, Data Science, Vir Biotechnology
Getting Dose Optimization Right with ctDNA: Sample Integrity, Logistics & Longitudinal Analysis
2:20 pm Serial Sampling at Scale: Protecting Plasma Quality, Logistics & Biobanking Across Longitudinal ctDNA & MRD Timepoints
- Maintaining consistent plasma collection and processing across every serial timepoint, so that quality does not drift between sites, visits or countries
- Coordinating global logistics and long-term biobanking so that longitudinal sample series stay complete, traceable and fit for retrospective ctDNA analysis
- Applying lessons from studies such as IMVIGOR-11, where serial sample operations underpinned the MRD readout, to growing pharma investment in MRD-guided development
2:45 pm Session Reserved for BioIVT
- Presentation details to be announced
3:15 pm Using ctDNA to Inform Dose Optimization & Characterize Resistance in a Phase I Combination Study
- Examining how changes in ctDNA levels from baseline can be used to explore dose effect and support dose optimization decisions in early-phase development
- Outlining how longitudinal ctDNA collection, from pretreatment through on-treatment timepoints, was built into a phase I combination trial with standard of care therapy in KITdriven gastrointestinal stromal tumor
- Profiling the mutational spectrum and mechanisms of resistance captured in ctDNA, including primary resistance to standard of care, to better characterize the patient population entering the study
3:45 pm Session Reserved for Biodesix
- Presentation details to be announced
Track B: Patient Selection & Diagnostics
Chair: Dimple Modi, Senior Director, Oncology Precision Medicine, Regeneron
Harnessing Liquid Biopsy to Advance Personalized Cancer Vaccine Trials: From Target Selection to Patient Stratification
2:20 pm Beyond Detection: Using ctDNA to Stratify Patients & Guide Personalized Cancer Vaccine Development in MRD
- Exploring how ctDNA positive versus negative status is being used to stratify patients in personalized cancer vaccine trials after surgery, and what a positive result does and does not tell us about clinical outcome
- Examining the open questions that sensitivity alone cannot answer, including how ctDNA relates to circulating tumor cells, how to interpret ctDNA shifts when immunotherapy destroys tumor, and the ethical implications of incidental findings from large panels in single-indication trials
- Sharing exploratory data and a trial designer’s perspective on what evidence is needed to link ctDNA to disease-free survival, and what that means for MRD as a regulatory endpoint
2:45 pm Session Reserved for Burning Rock Dx
- Presentation details to be announced
3:15 pm From Tumor to Plasma: Using ctDNA to Select Neoepitopes & Track Response in Personalized Cancer Vaccines
- Explaining how ctDNA is combined with tumor biopsy sequencing, matched blood normal and RNA sequencing to confirm that candidate neoepitopes are tumor-specific, abundant and worth targeting in a personalized vaccine
- Showing why selecting mutations carried by enough tumor cells matters for clinical efficacy, and how plasma analysis adds confidence where core biopsies may under sample the tumor
- Discussing monitoring the same mutations, and HPV16- specific ctDNA in HPV-driven cancers, during treatment, and correlating those changes with imaging and clinical response
3:45 pm Session Reserved for Caris Life Sciences
- Presentation details to be announced
4:15 pm Afternoon Break & Networking
Harnessing ctDNA Clearance Dynamics to Identify the Clinical Decision Making Faster Than Imaging
4:45 pm Integrating Longitudinal ctDNA-Based MRD & PETCT for Earlier Detection of Response & Relapse in B-Cell Malignancies Compared with Imaging Alone
- Further details to be released
5:10 pm Session Reserved for Pillar Biosciences
- Presentation details to be announced
5:40 pm Molecular Response Assessment in Ovarian Cancer: Clinical Experience from Azenosertib Studies
- Circulating tumor DNA (ctDNA) is increasingly being explored as a tool for monitoring treatment response in oncology. In ovarian cancer, where opportunities for early assessment of therapeutic activity remain limited, molecular response approaches have attracted growing interest
- This presentation will review the evolution of molecular response assessment in ovarian cancer and present recent clinical experience from azenosertib studies
- Data from plasma samples collected before and during treatment will be discussed alongside findings from previously published studies, highlighting both the promise and the practical challenges of implementing ctDNA-based response assessments in ovarian cancer clinical research
Beyond Mutations: Layering RNA, Methylation & Multi-Omic Signals to Sharpen Patient Diagnostics
4:45 pm Unlocking the Next Signal in Precision Oncology: RNA Liquid Biopsy for Early Detection & Drug Development
- Discovering novel cell-free RNA biomarkers through longread nanopore sequencing and machine learning to expand opportunities for early cancer and precancer detection
- Revealing dynamic tumor and host biology beyond genomic alterations to inform patient stratification, therapeutic response monitoring, and oncology drug development
- Integrating cell-free RNA with ctDNA, AI, and multimodal clinical data to advance next-generation liquid biopsy platforms for precision oncology
5:10 pm Session to be Confirmed
Inquire about remaining partnership opportunities at sponsor@hansonwade.com
5:40 pm Targeting Fatty Acid Metabolism with Carotuximab to Restore Androgen Receptor Inhibitor Sensitivity in Prostate Cancer
- Showing how carotuximab, a CD105-neutralizing antibody, blocks fatty acid oxidation in castration-resistant prostate cancer cells, increases oxidative stress and reshapes chromatin to restore sensitivity to androgen receptor signaling inhibitors
- Using epigenetic sequencing of circulating tumor DNA from pre- and post-treatment patient samples, supported by CT imaging, to reveal shared downregulation of androgen response, fatty acid oxidation and oxidative phosphorylation pathways across responders
- Highlighting how the kinetics of epigenetic remodeling, with an acute, extensive phase in poor responders versus stable, evenly distributed changes in strong responders, may distinguish treatment response